key: cord-0985575-3o3jfyyi
authors: Okamoto, Masashi; Kawada, Shoji; Fujii, Naoko; Matsukawa, Kazuki; Shimagami, Hiroshi; Ishikawa, Nachi; Ishida, Yutaka; Yamaguchi, Yuta; Kawamoto, Keisuke; Morita, Takayoshi; Kato, Yasuhiro; Higa, Shinji; Ogata, Atsushi; Kumanogoh, Atsushi
title: Rapid attenuation of anti‐SARS‐CoV‐2 antibody in patients with musculoskeletal diseases who reinitiated intensive immunosuppressive therapies after COVID‐19.
date: 2021-10-25
journal: Arthritis Rheumatol
DOI: 10.1002/art.42003
sha: f800e1ef3dab9b5dd8334db371e20a39175e6035
doc_id: 985575
cord_uid: 3o3jfyyi

nan

References 10

Supplementary Figure 1 Accepted Article This article is protected by copyright. All rights reserved.

We read with great interest the recently published American College of Rheumatology updated guideline for coronavirus disease 2019 (COVID-19) vaccination.

[1] Because the expected response to vaccination in many patients with rheumatic and musculoskeletal diseases (RMDs) receiving certain systemic immunomodulatory therapies was deemed likely to be blunted [2] [3] [4] , interrupting or otherwise optimizing the timing of some immunomodulatory therapies was recommended. However, the impairment of long-term memory immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [5] remains a concern in patients with RMDs requiring post-infection continuous immunomodulatory therapies.

Herein, we report the longitudinal antibody response in patients with RMDs Table 1 ). The patients were receiving intensive immunomodulatory therapies prior to COVID-19

infection and reinitiated immunosuppressive therapy after recovering from COVID-19.

The severity of COVID-19 was determined on the basis of the World Health

Organization Clinical Progression Scale.

[6] All patients exhibited sufficient antibody response to COVID-19 at 2-3 months post-infection. The initial anti-S antibody response was maintained until 9-11 months in most patients. Antibody retention in these patients was comparable to that reported in healthy individuals in previous studies.

[ 7, 8] Accepted Article 5 However, the initial favorable anti-S antibody titer decreased in two patients who reinitiated intensive immunosuppressive therapies after COVID-19 (Table 1) Figure-1 B) .

Intensive immunosuppressive therapy such as treatment with CSA may alter immune memory that contributes to long-term protective immunity. Conversely, anti-S antibody stability was maintained in a patient in whom the intake of intensive immunosuppressive therapies was suspended after COVID-19 (Supplementary Figure- 

This article is protected by copyright. All rights reserved. 

This article is protected by copyright. All rights reserved. 

This article is protected by copyright. All rights reserved.

American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal Diseases: Version 3. Arthritis Rheumatol

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Immune memory in individuals with COVID-19